To include your compound in the COVID-19 Resource Center, submit it here.

IMC-3C5: Phase I started

Eli Lilly began an open-label, dose-escalation, U.S. Phase I trial

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE